DNA Vaccine Strategies for the Treatment of Cancer

  • P. A. Benton
  • R. C. Kennedy
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 226)


A wide variety of immunotherapeutic strategies for the treatment of cancers is currently under investigation in both animal models and in clinical human trials (reviewed in Dranoff and Mulligan 1995). These include in vitro expansion and adoptive transfer of tumor-specific cytotoxic T cells in the presence or absence of recombinant cytokines (Rosenberg et al. 1985, 1986, 1988, 1989, 1991, 1993; Teng et al. 1991), tumor antigen-based vaccines (Cheever et al. 1986; Bright et al. 1994a; Conry et al. 1994; Stevenson et al. 1995), and tumor-reactive monoclonal antibodies conjugated to toxins (Trail et al. 1993; Vivetta et al. 1993). One of the most recent and innovative strategies has been based on the concept of genetic immunization. It is now well established that vaccination with plasmid DNA encoding a specific gene can elicit strong, long-lived protective immune responses to a variety of infectious agents (reviewed in Ulmer et al. 1996; Whalen 1996) as well as certain tumors (Conry et al. 1994; Nabel et al. 1994b; Stevenson et al. 1995; Bright et al. 1996; Corr et al. 1996; Schirmbeck et al. 1996). DNA vaccines directed at eliciting an immune response toward tumors appear to offer promise for both the prophylactic and therapeutic treatment of cancer.


Malignant Pleural Mesothelioma Simian Virus Tumor Immunity Genetic Immunization Protective Tumor Immunity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anderson JL, Martin RG, Chang C, Mora PT and Livingston DM (1977) Nuclear preparations of SV40 transformed cells contain tumor specific transplantation antigen activity. Virology 76:420–425PubMedCrossRefGoogle Scholar
  2. Bright RK, Beames B, Shearer MH and Kennedy RC (1996) Protection against a lethal tumor challenge with simian virus 40 transformed cells by the direct injection of DNA encoding SV40 large tumor antigen. Cancer Res 56:1126–1130PubMedGoogle Scholar
  3. Bright RK, Shearer MH and Kennedy RC (1994a) Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells. J Immunol 153:2064–2071PubMedGoogle Scholar
  4. Bright RK, Shearer MH and Kennedy RC (1994b) SV40 large tumor antigen associated synthetic peptides define native antigenic determinants and induce protective tumor immunity in mice. Mol Immunol 29:989–999Google Scholar
  5. Browning MJ and Bodmer WF (1992) MHC antigens and cancer: Implications for T-cell surveillance. Curr Opinion Immunol 4:613–618CrossRefGoogle Scholar
  6. Carrel S and Rimoldi D (1993) Melanoma associated antigens. Eur J Cancer 29A:1903–1907PubMedCrossRefGoogle Scholar
  7. Chang C, Martin RG, Livingston DM, Luborsky SW, Hu CP and Mora PT (1979) Relationship between T-antigen and tumor-specific transplantation antigen in simian virus 40 transformed cells. J Virol 29:69–75PubMedGoogle Scholar
  8. Cheever MA, Britzmann-Thompson D, Klarnet JP and Greenberg PI (1986) Antigen-driven long term- cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist longterm as functional memory T cells. J Exp Med 163:1100–1112PubMedCrossRefGoogle Scholar
  9. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P and Linsley PS (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093–1102PubMedCrossRefGoogle Scholar
  10. Ciernik IF, Berzofsky JA and Carbone DP (1996) Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J Immunol 156:2369–2375PubMedGoogle Scholar
  11. Cohen J (1993) Cancer vaccines get a shot in the arm. Science 262:841–843PubMedCrossRefGoogle Scholar
  12. Conry RM, LoBuglio AF, Kantor J, Schlom J, Loechel F, Moore SE, Sumerel LA, Barlow DL, S. A and Curiel DT (1994) Immune response to a carcinoembryonic antigen polynucleotide vaccine. Cancer Res 54:1164–1168PubMedGoogle Scholar
  13. Corr M, Lee DJ, Carson DA and Tighe H (1996) Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med 184:1555–1560PubMedCrossRefGoogle Scholar
  14. Cristiano RJ, Smith LC, Brinkley BR and Woo SL (1993a) Hepatic gene therapy: Efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. Proc Natl Acad Sci USA 90:11548–11552PubMedCrossRefGoogle Scholar
  15. Cristiano RJ, Smith LC and Woo SLC (1993b) Hepatic gene therapy: Adenovirus enhancement of receptor-mediated gene delivery and expression in primary hepatocytes. Proc Natl Acad Sci USA 90:2122–2126PubMedCrossRefGoogle Scholar
  16. Davis HL, Michel ML and Whalen RG (1995) Use of plasmid DNA for direct gene transfer and immunization. Ann New York Acad Sci 772:21–29CrossRefGoogle Scholar
  17. Dranoff G and Mulligan RC (1995) Gene transfer as cancer therapy. Adv Immunol 58:417–454PubMedCrossRefGoogle Scholar
  18. Eisen HN, Sakato N and Hall SJ (1975) Myeloma proteins as tumor-specific antigens. Transplant Proc 7:209–214PubMedGoogle Scholar
  19. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B and Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397–403PubMedCrossRefGoogle Scholar
  20. Foecking MK and Hofstetter H (1986) Powerful and versatile enhancer-promoter unit for mammalian expression vectors. Gene 45:101–105PubMedCrossRefGoogle Scholar
  21. Foley EJ (1953) Antigenic properties of methylcholanthrene-induced tumor in mice of the strain of origin. Cancer Res 13:835–837PubMedGoogle Scholar
  22. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K and Gilboa E (1990a) Retroviral vector- mediated g-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 50:7820–7825PubMedGoogle Scholar
  23. Gansbacher B, Zier K, Daniels B, Kronin K, Bannerji R and Gilboa E (1990b) Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172:1217–1224PubMedCrossRefGoogle Scholar
  24. Gooding LR (1977) Specificities of killing by cytotoxic lymphocytes generated in vivo and in vitro to syngeneic SV40 transformed cells. J Immunol 118:920–927PubMedGoogle Scholar
  25. Gross L (1943) Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res 3:326–333Google Scholar
  26. Hassett DE and Whitton JL (1996) DNA immunization. Trends in Microbiology 4:307–312PubMedCrossRefGoogle Scholar
  27. Hawkins RE, Winter G, Hamblin TJ, Stevenson FK and Russell SJ (1993) A genetic approach to idiotypic vaccination. J Immunother 14:273–278CrossRefGoogle Scholar
  28. Hawkins RE, Zhu D, Ovecka M, Winter G, Hamblin TJ, Long A and Stevenson FK (1994) Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain antibodies Fv personal vaccines. Blood 83:3279–3288PubMedGoogle Scholar
  29. Hui K, Grosveld F and Festenstein (1984) Rejection of transplantable leukemia cells following MHC DNA-mediated cell transformation. Nature 311:750–752PubMedCrossRefGoogle Scholar
  30. Irvine KR, Rao JB, Rosenberg SA and Restifo NP (1996) Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 156:238–245PubMedGoogle Scholar
  31. Kawakami Y, Robbins PF, Wang RF, Rosenberg SA (1996) Identification of tumor-regression antigens in melanoma. In: DeVita VT, Heilman S, Rosenberg SA (eds) Advances in oncology, Lippincott- Raven, Philadelphia, pp 3–21Google Scholar
  32. Kennedy RC, Dreesman GR, Butel JS and Lanford RE (1985) Suppression of in vivo tumor formation induced by simian virus 40-transformed cells in mice receiving anti-idiotypic antibodies. J Exp Med 161:1432–1449PubMedCrossRefGoogle Scholar
  33. Kennedy RC, Zhou E-M, Lanford RE, Chanh TC and Bona CA (1987) Possible role of anti-idiotypic antibodies in the induction of tumor immunity. J Clin Invest 80:1217–1224PubMedCrossRefGoogle Scholar
  34. Knowles BB, Koncar M, Pfizenmaier, K., Solter D, Aden DP and Trinchieri G (1979) Genetic control of the cytotoxic T cell response to SV40 tumor associated specific antigen. J Immunol 122:1798–1806PubMedGoogle Scholar
  35. Krieg P, Amtmann E, Jonas D, Fisher H, Zang K and Sauer G (1981) Episomal simian virus 40 genomes in human brain tumors. Proc Natl Acad Sci USA 10Google Scholar
  36. Mernaugh RL, Shearer MH, Bright RK, Lanford RE and Kennedy RC (1992) Idiotypic network components are involved in the murine immune response to simian virus 40 large tumor antigen. Cancer Immunol Immunother. 35:113–118PubMedCrossRefGoogle Scholar
  37. Moller P and Hammerling G (1992) The role of surface HLA-A, B, C molecules in tumor immunity. Cancer Surg 13:101–128Google Scholar
  38. Mule JJ, Shu S, Schwarz SL and Rosenberg SA (1984) Adoptive immunotherapy of established pulmonary métastasés with LAK cell and recombinant interleukin-2. Science 225:1487–89PubMedCrossRefGoogle Scholar
  39. Nabel EG, Yang Z-Y, Muller D, Chang AE, Gao X, Huang L, Cho KJ and Nabel GJ (1994a) Safety and toxicity of catheter gene delivery to the pulmonary vasculature in a patient with metastatic melanoma. Hum Gene Ther 5:1089–1094PubMedCrossRefGoogle Scholar
  40. Nabel GJ, Nabel EG, Yang Z, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D and Chang AE (1994b) Molecular genetic interventions for cancer. Cold Spring Harbor Symposia on Quantitative Biology 59:699–707PubMedGoogle Scholar
  41. Nabel GJ, Nabel EG, Yang Z-Y, Fox BA, Plautz GE, Gao X, Huang L, Shu S and Chang AE (1993) Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 90:11307–11311PubMedCrossRefGoogle Scholar
  42. Pass HI, Kennedy RC and Carbone M (1996) Evidence for and implications of SV40-like sequences in human mesotheliomas. In: Important advances in oncology 1996. Devita VT, Heilman S, Rosenberg SA, eds. Lippincott-Raven, Philadelphia pp 89–108Google Scholar
  43. Plautz GE, Yang ZY, Gao X, Huang L and Nabel GJ (1993) Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 90:4645PubMedCrossRefGoogle Scholar
  44. Prehn RT and Main JM (1957) Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18:769–778PubMedGoogle Scholar
  45. Raz E, Carson DA, Parker SE, Parr TB, Abai AM, Aichinger G, Gromkowski SH, Singh M, Lew D, Yankauckas MA, Baird SM and Rhodes GH (1994) Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA 91:9519–9523PubMedCrossRefGoogle Scholar
  46. Rosenberg SA (1991) Immunotherapy and gene therapy of cancer. Cancer Res (Suppl) 51:5074s–5079sGoogle Scholar
  47. Rosenberg SA, Anderson WF, Asher AL, Blaese MR, Ettinghausen SE, Hwu P, Kasid A, Mule JJ, Parkinson DR, Schwartzentruber DJ, Topalian SL, Weber JS, Yannelli JR, Yang JC and Linehan WM (1992a) Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for interleukin-2. Human Gene Therapy 3:75–90CrossRefGoogle Scholar
  48. Rosenberg SA, Anderson WF, Asher AL, Blaese MR, Ettinghausen SE, Hwu P, Kasid A, Mule JJ, Parkinson DR, Schwartzentruber DJ, Topalian SL, Weber JS, Yannelli JR, Yang JC and Linehan WM (1992b) Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for tumor necrosis factor. Human Gene Therapy 3:57–73CrossRefGoogle Scholar
  49. Rosenberg SA, Lotze MA, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C and Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients wiht metastatic cancer. N Eng J Med 313:1485–1492CrossRefGoogle Scholar
  50. Rosenberg SA, Lotze MT, Yang JC, Aebersold PA, Linehan WM, Seipp CA and White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 patients with cancer. Ann Surg 210:474–485PubMedCrossRefGoogle Scholar
  51. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM and Seipp CAea (1993) Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85:622–632PubMedCrossRefGoogle Scholar
  52. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP and White DE (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319:1676–1680PubMedCrossRefGoogle Scholar
  53. Rosenberg SA, Spiess P and Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318–1321PubMedCrossRefGoogle Scholar
  54. Roth C, Rochlitz C and Kourilsky P (1994) Immune response against tumors. Adv Immunol 57:281–351PubMedCrossRefGoogle Scholar
  55. Samson JH, Archer GE, Ashley DM, Fuchs HE, Hale LP, Dranoff G and Bigner DD (1996) Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the “immunologically privileged” central nervous system. Proc Natl Acad Sci USA 93:10399–10404CrossRefGoogle Scholar
  56. Schirmbeck R, Bohm W and Reimann J (1996) DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors. J Immunol 157:3550–3558PubMedGoogle Scholar
  57. Schirmbeck R, Zerrahn J, Kuhrober A, Kury E, Deppert W and Reimann J (1992) Immunization with soluble simian virus 40 large T antigen induces a specific response of CD3+ C4–CD8+ cytotoxic T lymphocytes in mice. Eur J Immunol 22:759–766PubMedCrossRefGoogle Scholar
  58. Schwartz RH (1992) Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71:1065–1068PubMedCrossRefGoogle Scholar
  59. Shearer MH, Bright RK and Kennedy RC (1993) Comparison of the humoral immune responses and tumor immunity in mice immunized with recombinant SV40 large tumor antigen and a monoclonal anti-idiotype. Cancer Res 53:5734–5739PubMedGoogle Scholar
  60. Stevenson FK, Zhu D, King CA, Ashworth LJ, Kumar S and Hawkins RE (1995) Idiotypic DNA vaccines against B-cell lymphoma. Immunol Rev 145:211–228PubMedCrossRefGoogle Scholar
  61. Tanaka K, Isselbacher KJ, Khoury G and Jay G (1985) Reversal of oncogenesis by the expression of H-2 K antigen following H-2 gene transfection. Science 228:26–30PubMedCrossRefGoogle Scholar
  62. Teng MN, Park BH, Koeppen HK, Tracey KJ, Fendly BM and Schreiber H (1991) Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc Natl Acad Sci USA 88:3535–3539PubMedCrossRefGoogle Scholar
  63. Tepper RI, Pattengale PK and Leder P (1989) Murine interleukin-4 displays potent antitumor activity in vivo. Cell 57:503–512PubMedCrossRefGoogle Scholar
  64. Tevethia SS, Flyer DC and Tjian R (1980) Biology of simian virus 40 (SV40) transplantation antigen (TrAg). VI. Mechanism of induction of SV40 transplantation immunity in mice by purified SV40 T antigen (D2 protein). Virology 107:13–23PubMedCrossRefGoogle Scholar
  65. Townsend SE and Allison JP (1993) Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259: 368–270PubMedCrossRefGoogle Scholar
  66. Trail P, Wilner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, Firestone RA, Hellstrom I and Hellstrom KE (1993) Cure of xenografted human carcinomas by BR96-doxorubucin immunocon- jugates. Science 261:212–215PubMedCrossRefGoogle Scholar
  67. Ulmer JB, Donnelly JJ and Liu MA (1996) DNA vaccines promising: a new approach to inducing protective immunity. ASM news 62:476–479Google Scholar
  68. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Feigner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, Hawe LA, Leander KR, Martinez D, Perry HC, Shiever JW, Montgomery DL and Liu MA (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745–1749PubMedCrossRefGoogle Scholar
  69. Vile RG and Hart IR (1993) In vitro and vivo targeting of gene expression to melanoma cells. Cancer Res 53:962–967PubMedGoogle Scholar
  70. Vivetta ES, Thorpe PE and Uhr JW (1993) Immunotoxins: magic bullets or misguided missiles. Immunol Today 14:252–259CrossRefGoogle Scholar
  71. Wagner E, Plank C, Zatloukal K, Cotten M and Birnsteiel ML (1992a) Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: Toward a synthetic virus-like gene-transfer vehicle. Proc Natl Acad Sci USA 89:7934–7938PubMedCrossRefGoogle Scholar
  72. Wagner E, Zatloukal K, Cotten M, Kirlappos H, Mechtler K, Curiel DT and Birnsteil ML (1992b) Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc Natl Acad Sci USA 89:6099–6103PubMedCrossRefGoogle Scholar
  73. Wallich R, Bulbuc N, Hammerling G, Katzav S, Segal S and Feldman M (1985) Abrogation of metastatic properties of tumor cells by de novo expression of H-2 K antigen following H-2 gene transfection. Nature 315:301–305PubMedCrossRefGoogle Scholar
  74. Wang B, Merva M, Dang K, Ugen KE, Williams WV and Weiner DB (1995) Immunization by direct DNA inoculation induces rejection of tumor cell challenge. Human Gene Ther 6:407–418CrossRefGoogle Scholar
  75. Watanabe Y, Kuribayashi K, Miyatake S, Nishihara K, Nakayama E, Taniyama R and Sakata T (1989) Exogenous expression of mouse interferon g cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 86:9456–9460PubMedCrossRefGoogle Scholar
  76. Whalen RG (1996) DNA vaccines for emerging infectious diseases: what if? Emerg Inf Dis 2:168–175CrossRefGoogle Scholar
  77. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A and Feigner PL (1990) Direct gene transfer into mouse muscle in vivo. Science 247:1465–1468PubMedCrossRefGoogle Scholar
  78. Xiang Z and Ertl HC (1995) Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 2:129–135PubMedCrossRefGoogle Scholar
  79. Zhu N, Liggitt D, Liu Y and Debs R (1993) Systemic gene expression after intravenous DNA delivery into adult mice. Science 261:209–211PubMedCrossRefGoogle Scholar
  80. Zimmerman W and Thompson J (1990) Recent developments concerning the carcinoembryonic gene family and their clinical applications. Tumor Biol 11:1–4CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • P. A. Benton
    • 1
  • R. C. Kennedy
    • 1
  1. 1.Department of Microbiology and ImmunologyUniversity of Oklahoma Health Sciences CenterOklahoma CityUSA

Personalised recommendations